The U.S. Centers for Disease Control and Prevention (CDC) has endorsed Gilead Sciences’ groundbreaking HIV prevention medication, lenacapavir, which has the potential to significantly reduce HIV transmission rates. This recommendation has sparked a strong response from patient advocacy groups, who are urging CVS Health to reconsider its recent decision to exclude the drug from its coverage plans. Lenacapavir, marketed as Yeztugo, was approved by the FDA just three months prior and offers nearly complete protection against HIV with a single dose administered every six months.
This endorsement aligns with a similar recommendation from the World Health Organization, highlighting the drug’s potential to transform HIV prevention strategies. However, the challenge remains for Gilead and healthcare providers to navigate insurance reimbursement, particularly as insurers may favor lower-cost generics like Truvada, which has been off-patent since 2021. Analysts predict that insurers will likely impose barriers, such as requiring patients to try generics before accessing this innovative treatment, potentially hindering its adoption in clinical practice.
Start your 7-day trial and see what the database can do →
